eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank

3/2021
vol. 13
 
Share:
Share:
abstract:
Original paper

The accuracy and dosimetric analysis of 3D-printing non-coplanar template-assisted iodine-125 seed implantation for recurrent chest wall cancer

Weijuan Gong
1
,
Yi Chen
1
,
Zhe Ji
1
,
Yuliang Jiang
1
,
Bin Qiu
1
,
Haitao Sun
1
,
Junjie Wang
1

  1. Department of Radiation Oncology, Peking University Third Hospital, Beijing, China
J Contemp Brachytherapy 2021; 13, 3: 273–279
Online publish date: 2021/05/18
View full text Get citation
 
Introduction
To investigate the accuracy and dosimetry of 3D-printing non-coplanar template (3D-PNCT)-assisted computed tomography (CT)-guided iodine-125 seed implantation (125I-SI) for recurrent chest wall cancer (rCWC).

Material and methods
This was a retrospective study of 19 patients with 22 rCWC treated with 3D-PNCT-assisted CT-guided 125I-SI, from Mar 2017 to Mar 2020 in our institute.

Results
Mean needle entrance deviation was 4.50 ±2.70 mm, mean angular deviation was 3.40 ±3.10 degrees, and mean depth deviation was 5.20 ±5.20 mm. No significant difference was found for dosimetric parameters (except conformity index) between pre-plan and post-plan; D90, D100, V100, V150, and V200 were 157.74 ±24.23 and 151.71 ±33.62 (p = 0.228), 85.36 ±34.09 and 70.46 ±23.48 (p = 0.067), 0.93 ±0.04 and 0.90 ±0.07 (p = 0.068), 0.64 ±0.16 and 0.64 ±0.16 (p = 0.984), and 0.35 ±0.17 and 0.37 ±0.18 (p = 0.382) for pre-plan and post-plan, respectively. Conformity index, external index, and homogeneity index were 0.57 ±0.16 and 0.52 ±0.15 (p = 0.007), 0.73 ±0.55 and 0.79 ±0.53 (p = 0.096), and 0.31 ±0.15 and 0.30 ±0.14 (p = 0.504) for pre-plan and post-plan, respectively. Median follow-up time was 8 months (range, 3-30 months). Complete response was observed in 4/22 (18.1%), partial response in 13/22 (59.1%), stable disease in 4/22 (18.1%), and progression disease in 1/22 (4.5%) of the cancers. Among patients with pain before 125I-SI, pain relief rate was 87.5% (7/8). No peri-operative complications of more than grade 2 were observed.

Conclusions
3D-PNCT-assisted CT-guided 125I-SI may be safe and feasible as palliative therapy for non-surgical candidates and painful patients with rCWC.

keywords:

chest wall cancer, 3D printing, 125I, seed implantation, brachytherapy

 
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.